Sarah Cannon Research Institute

🔍 Spotlight on Resilience: Mike's Journey with Ocular Melanoma 🔍 From thriving as a college football referee to facing the challenges of cancer, Mike's story is a testament to the power of perseverance and clinical trials. Under the expert care of Dr. Meredith McKean at Sarah Cannon Research Institute, Mike's life was enriched with renewed hope. Discover how Mike continues to pursue his passions and inspire others along the way: Read More https://bit.ly/4fE7PVU #HealthcareInnovation #PatientStories #SCRI

We are proud to share insights from our experts at Sarah Cannon Research Institute as featured in Fox News' article, "The Year in Cancer: Advances Made in 2024, Predictions for 2025." Discover how our oncologists, Dr. Krish Patel, Erika Hamilton, MD, Vivek Subbiah, MD, and Dr. Meredith McKean, are at the forefront of groundbreaking cancer treatments and what they anticipate for the future of cancer care. Together, let's continue to push the boundaries of what’s possible in the fight against cancer. 🔗 https://lnkd.in/eQpMi-U8 #CancerResearch #Oncology #HealthcareInnovation #SCRI

🌟 An Inspirational Journey: Meet Karen 🌟 We are honored to share the incredible story of Karen, a 66-year-old from Northeast Tennessee, who has been battling HER2+ breast cancer since 2007. After years of traditional treatments, Karen found hope through clinical trials at SCRI Oncology Partners. Under the care of Erika Hamilton, MD, Director of Breast Cancer Research, Karen enrolled in several trials, including one for an antibody drug conjugate (ADC) – a targeted therapy that brings powerful treatments directly to cancer cells, sparing healthy ones.   "Dr. Hamilton said that antibody drug conjugates are typically easier on the body, and I happily obliged!" Karen shared. After 42 rounds of ADC treatment, she experiences minimal side effects, allowing her to continue working full-time, volunteering, and enjoying life with her daughter.   Thanks to courageous patients like Karen, this ADC is now FDA-approved and available to all cancer patients. Her journey is a testament to the power of clinical trials and the hope they bring to patients and families.   Read more about Karen’s inspiring journey and the impact of our research. Together, we continue to advance cancer treatment and bring hope to those who need it most. https://lnkd.in/eTpeC8Qz #PatientStories #CancerResearch #Hope #SarahCannonResearchInstitute

🌟 An Inspirational Journey: Meet Karen 🌟 We are honored to share the incredible story of Karen, a 66-year-old from Northeast Tennessee, who has been battling HER2+ breast cancer since 2007. After years of traditional treatments, Karen found hope through clinical trials at SCRI Oncology Partners. Under the care of Erika Hamilton, MD, Director of Breast Cancer Research, Karen enrolled in several trials, including one for an antibody-drug conjugate (ADC) – a targeted therapy that brings powerful treatments directly to cancer cells, sparing healthy ones.   "Dr. Hamilton said that antibody-drug conjugates are typically easier on the body, and I happily obliged!" Karen shared. After 42 rounds of ADC treatment, she experiences minimal side effects, allowing her to continue working full-time, volunteering, and enjoying life with her daughter.   Thanks to courageous patients like Karen, this ADC is now FDA-approved and available to all cancer patients. Her journey is a testament to the power of clinical trials and the hope they bring to patients and families.   Read more about Karen’s inspiring journey and the impact of our research. Together, we continue to advance cancer treatment and bring hope to those who need it most. Read her full story: https://lnkd.in/eTpeC8Qz #PatientStories #CancerResearch #Hope #SarahCannonResearchInstitute

Congratulations to Erika Hamilton, MD, SCRI’s Director of Breast Cancer Research, on her election to the ASCO Nominating Committee! In this leadership role, Dr. Hamilton and her colleagues will recommend potential candidates for various American Society of Clinical Oncology (ASCO) elected positions over a three-year term. Dr. Hamilton continues to hold additional leadership positions on behalf of the ASCO community, serving as the ASCO Scientific Chair for ASCO 2025 and has been on ASCO’s Cancer Research Committee since 2023. She has served in several leadership roles over the course of her career, including being selected for the ASCO Leadership Development Class for 2021-2022, served as past chair of ASCO’s Scientific Committee for Metastatic Breast Cancer for 2019-2020, and was on ASCO’s Plenary Committee in 2023. Read more about this announcement here, and please join us in congratulating Dr. Hamilton! https://lnkd.in/eNrQBWwU

The Independent Data Monitoring Committee (IDMC) has recommended a move-forward dose in Part 2a of the potential registration-enabling trial for first-line HLA-A2-Negative Metastatic Uveal Melanoma (MUM). This significant milestone is based on the compelling clinical efficacy and safety observed with the darovasertib and crizotinib combination. As Dr. Meredith McKean, Director of Melanoma and Skin Cancer Research at Sarah Cannon Research Institute, highlights, "The IDMC recommendation is a critical advancement towards potentially bringing a new treatment option to MUM patients." We remain committed to advancing cancer research and bringing hope to those affected by this challenging disease. Stay tuned for more updates! #CancerResearch #ClinicalTrials #Melanoma #PrecisionMedicine #SarahCannonResearchInstitute SCRI Oncology Partners https://lnkd.in/eupg5wu9

It was a privilege to partner with The US Oncology Network to host an inspiring dinner at the San Antonio Breast Cancer Symposium. It was an incredible opportunity to connect with dedicated professionals, exchange insights, and explore the latest advancements in breast cancer care. We are honored to be part of this community focused on enhancing patient outcomes and driving oncology research forward. A special thank you to the entire team for making this event a success! #BreastCancerSymposium #HealthcareLeadership #OncologyAdvancements

SCRI Oncology Partners is now enrolling patients on the Phase III TIGeR-PaC clinical trial for individuals with locally advanced pancreatic cancer. SCRI’s Associate Director of Gastrointestinal Cancer Research, Dr. Meredith Sellers Pelster, MD, MSCI, serves as the study Principal Investigator in Nashville, TN,. The TIGeR-PaC trial will compare RenovoRx's innovative TAMP™ therapy platform and RenovoCath® delivery system with the current standard-of-care chemotherapy. With the primary goal of improving overall survival and minimizing side effects, we are eager to see the impact of this targeted drug delivery approach. Stay tuned for more updates as we work together to transform cancer care. Read the full press release: https://lnkd.in/e5UQij-n #CancerResearch #ClinicalTrials #Oncology #HealthcareInnovation #SCRI #RenovoRx #TIGeRPaC

And that’s a wrap for #ASH24! A standing ovation for all the Sarah Cannon Research Institute colleagues behind the 65+ abstracts and presentations at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. This year, we proudly showcased significant advancements across multiple disease states, reflecting the relentless dedication to improving care for patients worldwide. Behind every presentation and session is a story of collaboration, innovation, and a commitment to making a difference. At SCRI, patients are our purpose—their needs inspire every step of our journey in advancing cutting-edge research and care. Together, we’re shaping the future of hematology, one breakthrough at a time. Here’s to the remarkable work being done today—and the impact it will have tomorrow. #ASH24 #SCRI 

Yesterday at #ASH24, Dr. Haydar Frangoul (center) presented his research on Sickle Cell Disease, highlighting the promising results from Exagamglogene Autotemcel or exa-cel. Exa-cel is a gene therapy that reported durable clinical benefits for Severe Sickle Cell Disease, marking it as a significant advancement in the long-term treatment plan for patients. For more information,  check out NPR’s extensive coverage of the CRISPR story prior to approval. Read more about Abstract #4954 here: https://lnkd.in/gcd6E4hs #SickleCellDisease #SCRI